Endocrinology, Vol 126, 1981-1988, Copyright © 1990 by Endocrine Society

ARTICLES

Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: localization of binding to lactotropes

IE Wanke and OP Rorstad
Department of Medicine, University of Calgary, Alberta, Canada.

Vasoactive intestinal peptide (VIP) has been implicated as a physiological PRL-releasing factor; however, characterization of VIP receptors on normal pituitaries using radioligand-binding methods has been problematic. In this study we demonstrated specific receptors for VIP in anterior pituitary glands of female rats using HPLC-purified monoiodinated [Tyr(125I)10]VIP. Binding of VIP was reversible, saturable to receptor and radioligand, regulated by guanine nucleotides, and dependent on time and temperature. Scatchard analysis of competitive binding studies indicated high and low affinity binding sites, with equilibrium dissociation constants (Kd) of 0.19 +/- 0.03 and 28 +/- 16 nM, respectively. The corresponding maximum numbers of binding sites were 158 +/- 34 fmol/mg and 11.7 +/- 6.9 pmol/mg. Binding was specific, as peptides with structural homology to VIP were less than 100th as potent as VIP. The rank order of potency of the peptides tested was VIP greater than rat (r) peptide histidine isoleucine = human (h) PHI greater than rGRF greater than bovine GRF = porcine PHI = VIP-(10-28) greater than hGRF greater than secretin greater than apamin greater than glucagon. Radioligand binding was associated primarily with lactotrope-enriched fractions prepared by unit gravity sedimentation of dispersed anterior pituitary cells. VIP stimulated PRL release from cultured rat anterior pituitary cells, with an ED50 of 1 nM. These results, comprising the first identification of specific VIP receptors in normal rat anterior pituitary tissue using radioligand- binding methods, provide additional support for a biological role of VIP in lactotrope function.

This article has been cited by other articles:

				M Fernandez, F Sanchez-Franco, N Palacios, I Sanchez, and L Cacicedo IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1 J. Mol. Endocrinol., June 1, 2005; 34(3): 699 - 712. [Abstract] [Full Text] [PDF]

				Z. Rekasi, J. L. Varga, A. V. Schally, G. Halmos, P. Armatis, K. Groot, and T. Czompoly Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers Endocrinology, June 1, 2000; 141(6): 2120 - 2128. [Abstract] [Full Text] [PDF]

				Z. Rekasi, J. L. Varga, A. V. Schally, G. Halmos, K. Groot, and T. Czompoly Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro PNAS, February 1, 2000; 97(3): 1218 - 1223. [Abstract] [Full Text] [PDF]

				G. Halmos, A. V. Schally, J. L. Varga, A. Plonowski, Z. Rekasi, and T. Czompoly Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone PNAS, September 12, 2000; 97(19): 10555 - 10560. [Abstract] [Full Text] [PDF]